3SOF

http://biz.yahoo.com/bw/070427/20070427005460.html?.v=5

Hi http://biz.yahoo.com/pz/070430/118179.html

To today: Resistance is 0.1897 - Support is 0.1717. Today's opinion we go up.

Hi, - Support 0.17, Resistance 0.18

Hi 
http://www.primenewswire.com/newsroom/news.html?d=119642

Genesis Adds Major Pharmaceutical Company to Its Partnering Program
BEIJING, May 17, 2007 (PRIME NEWSWIRE) -- Genesis Technology Group, Inc. (OTCBB:GTEC) announced it has signed a leading Chinese pharmaceutical company as the sixth member of its private-to-public partnering program. Based on information provided by the Chinese company, fiscal 2006 revenues topped $92 million and net profits exceeded 16%.


"Our newest partner company is decidedly our largest to date," remarked Dr. Shaohua Tan, Genesis Director in Beijing. "Our U.S. executive team soon will assemble in China to conduct discussions on how to best utilize this well-established pharmaceutical company in our capital and growth program.

"Gold Horse International, GTEC's partner company engaged in construction and real estate development in Western China, has reached the final stage in the private-to-public program. Interested parties should remain alert as announcements are expected to be made near term. Genesis' other partner companies -- China Environmental Technologies, Oriental Health Beverages and Sino Steel Structures -- are at various stages of the U.S. auditing process.

"We cannot offer a timeline for any of these partner companies to graduate to U.S. public company status. With CSRC regulations and the challenges of performing due diligence on each prospect, it remains a difficult and expensive process. Lotus (OTCBB:LTUS) remains a symbol of our success, and we are confident our other partner companies can join its rank in the future," concluded Dr. Tan.

About Genesis Technology Group, Inc.

Genesis Technology Group, Inc. (d/b/a Genesis China and GTEC) is a U.S. public company that earns, enhances and markets equity positions in small to mid-sized Chinese enterprises. Commitment, dedication, and expertise are the key components to the Genesis "Mission Statement." It has created a successful profit center by incubating Chinese companies in a wide range of sectors, creating so-coined "partner companies." Genesis makes a long-term commitment with management consultation, board of directors composition, creation and implementation of successful business models, which include expansion of markets in China and abroad. To help drive the success and profitability of these operations, Genesis provides resources and proficiency to maximize partners' leadership potential in China and attempts to increase high-margin, predictable earnings. For more information, visit http://www.genesis-china.net.

Safe Harbor Statement

Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions -- especially those relating to China, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws, restrictions and regulations on doing business in a foreign country, in particular China, and conditions of equity markets. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

Today: support 0.1347, resistance 0.1627

Hi
From: http://www.newratings.com/analyst_news/article_1534742.html

Genesis Technology "speculative buy"

Friday, May 18, 2007 3:27:15 AM ET
JM Dutton & Associates

NEW YORK, May 18 (newratings.com) - Analyst Stanley Ng of JM Dutton maintains his "speculative buy" rating on Genesis Technology Group (ticker: GTEC). The 12-month target price is set to $0.22.

In a research note published yesterday, the analyst mentions that the company has added a big Chinese pharmaceutical company to its partnering programme. The news is expected to have a favourable impact on Genesis Technology's share price going forward, and confirms the company's ability to involve quality companies in its private-to-public partnering programme, the analyst says.

Hi:

From: http://www.newratings.com/analyst_news/article_1537389.html

Genesis Technology "speculative buy"

Wednesday, May 23, 2007 4:56:29 AM ET
JM Dutton & Associates

NEW YORK, May 23 (newratings.com) - Analyst Stanley Ng of JM Dutton maintains his "speculative buy" rating on Genesis Technology Group Inc (ticker: GTEC). The 12-month target price is set to $0.22.

In a research note published yesterday, the analyst mentions that the company has posted net losses of about $1.63 million for the six months ended March 31 due to substantial expenses being incurred and no revenues being recognized. There was no recognition of revenues during the period, since no private-to-public projects were competed in the timeframe, the analyst adds. Genesis Technology is expected to be able to complete two projects during FY07 and three projects during FY08, JM Dutton says.

from: http://www.primenewswire.com/newsroom/news.html?d=120104

Genesis Pharmaceutical Partner, Lotus Pharmaceuticals, Releases First Quarter Results With Revenues Increasing by Nearly 27 Percent
BOCA RATON, Fla., May 23, 2007 (PRIME NEWSWIRE) -- Genesis Technology Group, Inc. (OTCBB:GTEC) announced that its partner company, Lotus Pharmaceuticals, Inc. (OTCBB:LTUS), released its first quarter results with revenues increasing by 26.73% and working capital reaching nearly $10 million.


The Lotus 10-QSB filing showed total revenues for the three months ended March 31, 2007 were $8,289,535 as compared to total revenues of $6,541,095 for the three months ended March 31, 2006, an increase of $1,748,440 or approximately 26.73%. Lotus reported income from operations of $1,129,779 for the three months ended March 31, 2007. The Company's working capital position increased $1,292,456 to $9,938,532 at March 31, 2007 from $8,646,076 at December 31, 2006.

In its well-established private-to-public program, Genesis has five additional contract partners: (1) Gold Horse International, in the final stage of the program before attaining public company status; (2) China Environmental Technologies, in the final stage of the U.S. auditing process; (3) Oriental Health Beverages, in the final stage of the U.S. auditing process; (4) Sino Steel Structures, in the pre-audit and pre-legal phase; and (5) LJ Pharmaceuticals, in the pre-audit and pre-legal phase.

Today: support 0.1413, resistance 0.1593, opinion BUY

Hi

Hi

from: http://www2.barchart.com/news.asp?sym=GTEC

Press Release Source: Genesis Technology Group, Inc.


Genesis Technology Group Releases Third Quarterly Report Showing Net Assets of $7.6 Million, An Increase of 47.5 Percent
Tuesday August 21, 6:30 am ET


BOCA RATON, Fla., Aug. 21, 2007 (PRIME NEWSWIRE) -- Genesis Technology Group, Inc. (OTC BB:GTEC.OB - News) has released its third quarterly report for the period ended June 30, 2007. Net assets were approximately $7,608,000 compared to $5,221,000 on September 30, 2006, an increase of 45.7 percent.
CFO Adam Wasserman summarized: ``For the nine months ended June 30, 2007, we reported revenues of $3,035,000 as compared to $13,333 for the nine months ended June 30, 2006 which was attributable to a Share Exchange Agreement closed on June 29, 2007 by Speedhaul Holdings, Inc., Inc., a publicly-trading company (OTC BB:SPEH.OB - News), whereby GEP, our 51 percent-owned subsidiary, received 16,750,000 restricted common shares of SPEH for services performed in helping Gold Horse International and the Jin Ma Companies facilitate the merger with SPEH and for other business development services. For the nine months ended June 30, 2007, we reported net losses of $1,763,459 as compared to net income of $308,800 for the nine months ended June 30, 2006. At June 30, 2007, our net assets were approximately $7,608,000 compared to $5,221,000 at September 30, 2006, an increase of 45.7 percent.''

CEO Gary L. Wolfson added: ``Our immediate focus is completing the third private-to-public program for another Chinese partner company. If we can achieve this success in the coming six weeks, Genesis could boast of completing three such transformations in a 12-month period, quite an achievement. Genesis partner companies, attaining public company status in the U.S., would be Lotus Pharmaceuticals (OTC BB:LTUS.OB - News), Gold Horse International, and the new Green Power Technologies. Our current business model, although subject to burdensome regulations both in the U.S. and China, is effective and rewarding.''

Opinion: Price 0.0980, Support 0.0947, Resistance 0.1047 HOLD

Press Release Source: Genesis Technology Group, Inc.


Genesis Technology Group Merges With Chinese Pharmaceutical: 'Crowning Achievement' Says Management
Tuesday October 2, 9:34 am ET


BOCA RATON, Fla., Oct. 2, 2007 (PRIME NEWSWIRE) -- Genesis Technology Group, Inc. (OTC BB:GTEC.OB - News) has entered into a reverse merger with a company that owns and controls Laiyang Jiangbo Pharmaceuticals Co., Ltd. (``LJPC''), a Chinese pharmaceutical company. For its fiscal year ended June 30, 2007, the Company reported total revenue of $76,000,000; net income of $22,000,000; total assets of $55,000,000; and cash on hand of $17,000,000.

Located in a coastal city in Shandong Province, LJPC underwent an official audit by Moore Stephens Wurth Frazer and Torbet, LLP of Los Angeles, California, in addition to a rigorous due diligence process by Genesis management and consultants.

Based on research performed by a U.S. consulting firm and merchant bank, which inspected the LJPC facilities in Laiyang City last month, revenues have grown by an average of 187% over the previous two years, and net income has risen by an average of 748% over the same period.

Mr. Gary L. Wolfson, Genesis CEO since August 2002, reported: ``Since early 2003, Genesis management has earnestly and methodically sought a merger partner. Under the guidance of Dr. Shaohua Tan in China, we screened numerous candidates, and none could match the strength and potential of Laiyang Jiangbo Pharmaceuticals.

``It is an honor to turn over the future of the merged company to the leadership of Mr. Wubo Cao and his experienced team. Mr. Cao shall serve as the Chairman and Chief Executive Officer. It is our belief that the existing Genesis shareholders will be rewarded for their patience and dedication. In many ways, this merger is the crowning achievement of many years of effort and planning by Genesis management.

``The details of the merger will be explained fully in filings with the Securities & Exchange Commission and in a letter to be posted on our website http://www.genesis-china.net,'' explained Mr. Wolfson.

About Genesis Technology Group, Inc.

Genesis Technology Group, Inc. (d/b/a Genesis China and GTEC) is a U.S. public company that partners with qualified Chinese companies to expand their domestic and international market opportunities. The customized private-to-public program seeks to tap in to Western capital markets to attain this goal. Commitment, dedication, and expertise are the key components to the Genesis ``Mission Statement.'' It has created a successful profit center by incubating Chinese companies in a wide range of sectors, creating so-coined ``partner companies.'' Genesis makes a long-term commitment with management consultation, board of directors' composition, creation and implementation of successful business models, which include expansion of markets in China and abroad. To help drive the success and profitability of these operations, Genesis provides resources and proficiency to maximize partners' leadership potential in China and attempts to increase high-margin, predictable earnings. The forgoing description is prior to completion of the merger, which has resulted in Genesis Pharmaceutical Enterprises, Inc., the name of the merged company. For more information, visit http://www.genesis-china.net.

Safe Harbor Statement and Disclaimer

Certain statements set forth in this press release constitute ``forward-looking statements''. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words ``estimate'', ``project'', ``intend'', ``forecast'', ``anticipate'', ``plan'', ``planning'', ``expect'', ``believe'', ``will likely'', ``should'', ``could'', ``would'', ``may'' or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions -- especially those relating to China, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws, restrictions and regulations on doing business in a foreign country, in particular China, and conditions of equity markets. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission. The capital and growth program, the Company's central profit center, has specific risks and liabilities. Followers of our business model must understand that, until the Chinese partner company officially reaches public company status and files its initial Form 8-K, a high degree of risk exists that the partner may not ever attain that status. While receipt of a significant equity position in these companies is contractual, Genesis still recognizes that such compensation is conditional on performance and specific deliverables.

Contact:
          Genesis Pharmaceutical Enterprises, Inc.
          Elsa Sung, Chief Financial Officer
          (800) 867-0078, ext. 602
          Fax: (561) 988-9890
          [email protected]
          7900 Glades Road, Suite 420
          Boca Raton, Florida 33434
--------------------------------------------------------------------------------
Source: Genesis Technology Group, Inc.

Quote from: setravis on October 02, 2007, 03:53:43 PM
Press Release Source: Genesis Technology Group, Inc.

Thank you, I applaud

How about that closing chart...

Press Release Source: Genesis Technology Group, Inc.


Genesis Technology Group Posts Letter to Shareholders Detailing Merger With Chinese Pharmaceutical Company
Wednesday October 3, 8:30 am ET


BOCA RATON, Fla., Oct. 3, 2007 (PRIME NEWSWIRE) -- Genesis Technology Group, Inc. (OTC BB:GTEC.OB - News) announced on Monday that it had completed a reverse merger with a company that owns and controls Laiyang Jiangbo Pharmaceuticals Co., Ltd. (``LJPC''), a Chinese pharmaceutical company.
To inform its shareholders and interested parties, the Company has posted on its website a detailed letter from management, explaining the structure and history of the merger, a profile of LJPC, and the future of the merged company, now known as Genesis Pharmaceutical Enterprises, Inc. The letter, in its entirety, is accessible at http://www.genesis-china.net. Additional information is available under recent filings with the Securities & Exchange Commission.


Located in a coastal city in Shandong Province, LJPC underwent an official audit by Moore Stephens Wurth Frazer and Torbet, LLP of Los Angeles, California, in addition to a rigorous due diligence process by Genesis management and consultants. The law firm of Richardson & Patel P.A., also located in L.A., represented LJPC during the merger process.

About Genesis Technology Group, Inc.

Genesis Technology Group, Inc. (d/b/a Genesis China and GTEC) is a U.S. public company that partners with qualified Chinese companies to expand their domestic and international market opportunities. The customized private-to-public program seeks to tap in to Western capital markets to attain this goal. Commitment, dedication, and expertise are the key components to the Genesis ``Mission Statement.'' It has created a successful profit center by incubating Chinese companies in a wide range of sectors, creating so-coined ``partner companies.'' Genesis makes a long-term commitment with management consultation, board of directors' composition, creation and implementation of successful business models, which include expansion of markets in China and abroad. To help drive the success and profitability of these operations, Genesis provides resources and proficiency to maximize partners' leadership potential in China and attempts to increase high-margin, predictable earnings. The forgoing description is prior to completion of the merger, which has resulted in Genesis Pharmaceutical Enterprises, Inc., the name of the merged company. For more information, visit http://www.genesis-china.net.

Safe Harbor Statement and Disclaimer

Certain statements set forth in this press release constitute ``forward-looking statements''. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words ``estimate'', ``project'', ``intend'', ``forecast'', ``anticipate'', ``plan'', ``planning'', ``expect'', ``believe'', ``will likely'', ``should'', ``could'', ``would'', ``may'' or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions -- especially those relating to China, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws, restrictions and regulations on doing business in a foreign country, in particular China, and conditions of equity markets. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission. The capital and growth program, the Company's central profit center, has specific risks and liabilities. Followers of our business model must understand that, until the Chinese partner company officially reaches public company status and files its initial Form 8-K, a high degree of risk exists that the partner may not ever attain that status. While receipt of a significant equity position in these companies is contractual, Genesis still recognizes that such compensation is conditional on performance and specific deliverables.


Contact:
          Genesis Pharmaceutical Enterprises, Inc.
          Elsa Sung, Chief Financial Officer
          (800) 867-0078, ext. 602
          Fax: (561) 988-9890
          [email protected]
          7900 Glades Road, Suite 420
          Boca Raton, Florida 33434
--------------------------------------------------------------------------------
Source: Genesis Technology Group, Inc.

On the move early.......

+22.58%.......Volume @ 3,059,230

Press Release Source: Genesis Technology Group Inc.


Genesis Technology Group Retains CCG Elite
Wednesday October 24, 11:17 am ET


LOS ANGELES and LAIYANG, China, Oct. 24 /Xinhua-PRNewswire-FirstCall/ -- Genesis Technology Group Inc. (OTC Bulletin Board: GTEC - News; to be known as Genesis Pharmaceutical Enterprises, Inc.) ("GTEC" or "the Company"), a leading pharmaceutical company in the People's Republic of China ("PRC"), today announced that it has retained CCG Elite to design and execute its investor relations campaign.


Genesis, through its wholly-owned subsidiary Laiyang Jiangbo Biotech Technologies Co., Ltd. ("JiangBo"), is engaged in the research, development, manufacture and sale of pharmaceutical products in the PRC. One of the major pharmaceutical companies in the PRC, Genesis offers a full product line of both western medical drugs and Chinese herbal-based medical drugs in tablet, capsule and granule forms. For the year ending June 30, 2007, net sales for Genesis totaled $76.2 million, up approximately 55 percent from $49.2 million in 2006.

"We are a rapidly growing, large non-state-owned pharmaceutical producer in Shandong Province," said Mr. Cao Wubo, the Chairman and CEO of Genesis Technology Group. "We look forward to working with CCG Elite to increase our visibility in both the investment community and with the financial media as we continue to execute our growth strategy."

Pharmaceutical demand in the PRC is forecast to expand by more than 13 percent annually to reach RMB385 billion (about US$51 billion) by 2010. Consumption and production of pharmaceuticals in the PRC is expected to increase rapidly over the long term because of strong economic growth, changing demographic patterns, and the reform and expansion of health care systems.

"JiangBo is a large pharmaceuticals producer with products distributed via hospital and medical outlets in China, with an advanced technology, an experienced management team and a strong, competitive marketing presence," said Crocker Coulson, President of CCG Elite. "The company is well-positioned to take advantage of increasing demand for pharmaceuticals in China. We intend to assist the company to develop a broader following with fund managers and analysts focusing on high growth equities from China through an integrated investor relations program."

The Company maintains a representative office in the United States, where its Chief Financial Officer and a support staff are located. For more information, refer to http://www.genesis-china.net.

About CCG Elite

CCG Elite is uniquely positioned to provide an outsourced, high-level investor relations solution that combines in-depth understanding of Asia's corporate culture and economic scene with a direct pipeline into the leading funds and broker-dealers in the United States. CCG Elite is a global, full- service investor relations agency with corporate headquarters in Los Angeles, and offices in New York, Newport Beach, Dallas, Hong Kong and Beijing. For further information, contact CCG Elite or visit the company's website at http://www.ccgelite.com.

About Genesis Technology Group, Inc.

Genesis, through its wholly-owned subsidiary Laiyang Jiangbo Biotech Technologies Co., Ltd. ("JiangBo"), is engaged in the research, development, manufacture and sale of pharmaceutical products in the PRC. One of the major pharmaceutical companies in the PRC, Genesis offers a full product line of both western medical drugs and Chinese herbal-based medical drugs in tablet, capsule and granule forms. Jiangbo has several Certificates of Good Manufacturing Practices for Pharmaceutical Products from the Shandong State Drug Administration, and currently produces 5 major product categories in 3 forms.

Safe Harbor Statement

Certain statements set forth in this press release constitute "forward- looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential rights and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions -- especially those relating to China, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws, restrictions and regulations on doing business in a foreign country, in particular China, and conditions of equity markets. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.


    For more information, please contact:

     Genesis Technology Group
     Ms. Elsa Sung, CFO
     Phone: +1-800-867-0078 ext. 602
     Email: [email protected]

     CCG Elite Investor Relations Inc.
     Mr. Crocker Coulson, President
     Phone: +1-646-213-1915 (New York)
     Email: [email protected]
--------------------------------------------------------------------------------
Source: Genesis Technology Group Inc.